David Steensma
David Steensma
Novartis Institutes for Biomedical Research (formerly Dana-Farber Cancer Institute/Harvard Medical
Verified email at
Cited by
Cited by
Hoffbrand's essential haematology
V Hoffbrand, DP Steensma
John Wiley & Sons, 2019
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
DP Steensma, R Bejar, S Jaiswal, RC Lindsley, MA Sekeres, ...
Blood, The Journal of the American Society of Hematology 126 (1), 9-16, 2015
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
AD Pardanani, RL Levine, T Lasho, Y Pikman, RA Mesa, M Wadleigh, ...
Blood 108 (10), 3472-3476, 2006
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
RC Lindsley, BG Mar, E Mazzola, PV Grauman, S Shareef, SL Allen, ...
Blood, The Journal of the American Society of Hematology 125 (9), 1367-1376, 2015
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
J Bohlius, K Schmidlin, C Brillant, G Schwarzer, S Trelle, J Seidenfeld, ...
The Lancet 373 (9674), 1532-1542, 2009
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes
DP Steensma, GW Dewald, TL Lasho, HL Powell, RF McClure, RL Levine, ...
Blood 106 (4), 1207-1209, 2005
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
R Bejar, A Lord, K Stevenson, M Bar-Natan, A Pérez-Ladaga, J Zaneveld, ...
Blood, The Journal of the American Society of Hematology 124 (17), 2705-2712, 2014
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes
R Bejar, KE Stevenson, BA Caughey, O Abdel-Wahab, DP Steensma, ...
Journal of clinical oncology 30 (27), 3376, 2012
Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation
R Bejar, KE Stevenson, B Caughey, RC Lindsley, BG Mar, P Stojanov, ...
Journal of clinical oncology 32 (25), 2691, 2014
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial
DP Steensma, MR Baer, JL Slack, R Buckstein, LA Godley, ...
Journal of clinical oncology 27 (23), 3842, 2009
A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia
RA Mesa, DP Steensma, A Pardanani, CY Li, M Elliott, SH Kaufmann, ...
Blood, The Journal of the American Society of Hematology 101 (7), 2534-2541, 2003
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms
O Wolach, RS Sellar, K Martinod, D Cherpokova, M McConkey, ...
Science translational medicine 10 (436), eaan8292, 2018
The public repository of xenografts enables discovery and randomized phase II-like trials in mice
EC Townsend, MA Murakami, A Christodoulou, AL Christie, J Köster, ...
Cancer cell 29 (4), 574-586, 2016
Bone marrow niches in haematological malignancies
S Méndez-Ferrer, D Bonnet, DP Steensma, RP Hasserjian, IM Ghobrial, ...
Nature Reviews Cancer 20 (5), 285-298, 2020
Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes
DA Sallman, AE DeZern, G Garcia-Manero, DP Steensma, GJ Roboz, ...
Journal of clinical oncology 39 (14), 1584, 2021
The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates
A Tefferi, TL Lasho, SM Schwager, DP Steensma, RA Mesa, CY Li, ...
British journal of haematology 131 (3), 320-328, 2005
The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
RA Mesa, S Schwager, D Radia, A Cheville, K Hussein, J Niblack, ...
Leukemia research 33 (9), 1199-1203, 2009
The myelodysplastic syndromes: diagnosis and treatment
DP Steensma, JM Bennett
Mayo Clinic Proceedings 81 (1), 104-130, 2006
Recent developments in myelodysplastic syndromes
R Bejar, DP Steensma
Blood, The Journal of the American Society of Hematology 124 (18), 2793-2803, 2014
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value
MM Patnaik, TL Lasho, JM Hodnefield, RA Knudson, RP Ketterling, ...
Blood, The Journal of the American Society of Hematology 119 (2), 569-572, 2012
The system can't perform the operation now. Try again later.
Articles 1–20